F. C. Detterbeck, D. J. Boffa, A. W. Kim, and L. T. Tanoue, The eighth edition lung Cancer stage classification, Chest, vol.151, issue.1, pp.193-203, 2017.

K. S. Albain, J. J. Crowley, M. Leblanc, and R. B. Livingston, Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience, J Clin Oncol, vol.9, issue.9, pp.1618-1644, 1991.

T. M. De-pas, F. De-braud, and G. Catalano, Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era, Ann Thorac Surg, vol.83, issue.1, pp.231-235, 2007.

D. B. Shultz, A. R. Filippi, J. Thariat, F. Mornex, B. W. Loo et al., Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer, J Thorac Oncol, vol.9, issue.10, pp.1426-1459, 2014.

N. Group, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J Clin Oncol, vol.26, issue.28, pp.4617-4642, 2008.

J. Helou, I. Thibault, and I. Poon, Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter, Int J Radiat Oncol Biol Phys, vol.98, issue.2, pp.419-446, 2017.

D. R. Gomez, G. R. Blumenschein, and J. J. Lee, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after firstline systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, vol.17, issue.12, pp.1672-82, 2016.

D. R. Gomez, Y. Niibe, and J. Y. Chang, Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer, Pulm Med, p.396592, 2012.

D. De-ruysscher, R. Wanders, and L. E. Hendriks, Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous Oligometastases treated in a prospective phase II trial (NCT 01282450), J Thorac Oncol, vol.13, issue.12, pp.1958-61, 2018.

S. L. Lewis, S. Porceddu, and N. Nakamura, Definitive stereotactic body radiotherapy (SBRT) for Extracranial Oligometastases: an international survey of >1000 radiation oncologists, Am J Clin Oncol, vol.40, issue.4, pp.418-440, 2017.

C. Collen, N. Christian, and D. Schallier, Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, vol.25, issue.10, pp.1954-1963, 2014.

G. H. Griffioen, D. Toguri, and M. Dahele, Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors, Lung Cancer, vol.82, issue.1, pp.95-102, 2013.

P. Iyengar, B. D. Kavanagh, and Z. Wardak, Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer, J Clin Oncol, vol.32, issue.34, pp.3824-3854, 2014.

M. Hecht, L. Zimmer, and C. Loquai, Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients, Ann Oncol, vol.26, issue.6, pp.1238-1282, 2015.

K. L. Stephans, T. Djemil, and C. Diaconu, Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity, Int J Radiat Oncol Biol Phys, vol.90, issue.1, pp.197-202, 2014.

J. E. Chaft, G. R. Oxnard, and C. S. Sima, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design, Clin Cancer Res, vol.17, issue.19, pp.6298-303, 2011.

F. Hu, J. Xu, and B. Zhang, Efficacy of local consolidative therapy for Oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations, Clin Lung Cancer, vol.20, issue.1, pp.81-90, 2019.

F. Barlesi, J. Mazieres, and J. P. Merlio, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT), Lancet, vol.387, pp.1415-1441, 2016.

A. J. Weickhardt, B. Scheier, and J. M. Burke, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, vol.7, issue.12, pp.1807-1821, 2012.

P. Iyengar, Z. Wardak, and D. E. Gerber, Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial, JAMA Oncol, vol.4, issue.1, p.173501, 2018.

D. A. Palma, R. A. Olson, and S. Harrow, Stereotactic ablative radiation therapy for the comprehensive treatment of Oligometastatic tumors (SABR-COMET): results of a randomized trial, Int J Radiat Oncol Biol Phys, vol.102, issue.3, pp.3-4, 2018.

, Correction: Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer, BMJ Open, vol.9, issue.5, pp.20690-20691, 2019.

, Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases -Full Text View -ClinicalTrials.gov

J. Y. Chang, S. Senan, and M. A. Paul, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Oncol, vol.16, issue.6, pp.630-637, 2015.

J. K. Salama, M. D. Hasselle, and S. J. Chmura, Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease, Cancer, vol.118, issue.11, pp.2962-70, 2012.

N. H. Lester-coll, C. E. Rutter, T. J. Bledsoe, S. B. Goldberg, R. H. Decker et al., Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases, Int J Radiat Oncol Biol Phys, vol.95, issue.2, pp.663-672, 2016.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations